# Imaging and Targeted Auger Radiotherapy of High-Grade Glioma

> **NIH NIH R01** · WASHINGTON UNIVERSITY · 2020 · $714,528

## Abstract

SUMMARY/ABSTRACT
Glioblastoma (GBM) is a highly aggressive, malignant, primary brain tumor. Maximal neurosurgical tumor
resection, followed by highly conformal radiation and concurrent chemotherapy, remains the standard of care for
GBM patients. These tumors inevitably recur. Given the dismal prognosis, improved technologies are
desperately needed to enable better treatment of recurrent GBM. An additional complicating factor is the
diagnostic challenge of non-invasively discriminating recurrent GBM from radiation necrosis (RN). PARP-1, an
enzyme involved in DNA repair, is selectively overexpressed in the nuclei of glioma cells. In recent years,
radiolabeled PARP-1 inhibitors have been investigated for the non-invasive imaging of PARP-1 expression in
glioma, as well as other tumors. Radiolabeled PARP-1 inhibitors have also been proposed for targeted
radiotherapy, though, to date, there have only been two published reports. In this application, we propose to
examine existing radiolabeled PARP-1 inhibitors and to synthesize and evaluate novel radiolabeled PARP-1
inhibitors, as theranostic agents for glioblastoma. Radionuclides of iodine and bromine are proposed for imaging
and therapeutic studies. Herein, we will focus on positron-emitting radionuclides for PET imaging and Auger-
emitting radionuclides for therapy. These studies will be supported by advanced MRI experiments aimed at
characterizing the physiology of tumors and RN, and for assessing therapeutic response. The aims of the
proposal are to: i) synthesize various established and novel radiolabeled PARP-1 inhibitors, and evaluate their
uptake and efficacy in vitro, ii) evaluate radiolabeled PARP-1 inhibitors for uptake in murine models of
glioblastoma and experimental radiation necrosis, and iii) determine the therapeutic efficacy of the PARP-1
inhibitors in murine models of glioblastoma. This grant application will be led by a quality team of experts,
specializing in models of experimental radiation necrosis and MR imaging (Dr. Joel Garbow); targeted radiation
therapy and PET imaging (Dr. Buck Rogers); radioligand development and labeling (Dr. Dong Zhou); in vitro
binding assays and autoradiography (Dr. Jinbin Xu); and radiolabeled PARP-1 inhibitors and glioma animal
models (Dr. Thomas Reiner). If successful, our approach will provide a new technology driven paradigm for
treating patients with recurrent glioblastoma.

## Key facts

- **NIH application ID:** 9972141
- **Project number:** 1R01EB029752-01A1
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Joel Richard Garbow
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $714,528
- **Award type:** 1
- **Project period:** 2020-05-01 → 2024-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9972141

## Citation

> US National Institutes of Health, RePORTER application 9972141, Imaging and Targeted Auger Radiotherapy of High-Grade Glioma (1R01EB029752-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9972141. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*